RU95120155A - DRUG IMMUNO-CORRECTIVE ACTION ON THE BASIS OF CELL SUSPENSION AND METHOD FOR TREATING DIABETES WITH USE OF THIS DRUG - Google Patents

DRUG IMMUNO-CORRECTIVE ACTION ON THE BASIS OF CELL SUSPENSION AND METHOD FOR TREATING DIABETES WITH USE OF THIS DRUG

Info

Publication number
RU95120155A
RU95120155A RU95120155/14A RU95120155A RU95120155A RU 95120155 A RU95120155 A RU 95120155A RU 95120155/14 A RU95120155/14 A RU 95120155/14A RU 95120155 A RU95120155 A RU 95120155A RU 95120155 A RU95120155 A RU 95120155A
Authority
RU
Russia
Prior art keywords
drug
cell suspension
immunocorrective
immuno
basis
Prior art date
Application number
RU95120155/14A
Other languages
Russian (ru)
Other versions
RU2126260C1 (en
Inventor
А.С. Ефимов
А.И. Смикодуб
А.В. Новицкая
Original Assignee
Центр эмбриональных тканей "ЭМСЕЛЛ"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from UA94020324A external-priority patent/UA27048C2/en
Application filed by Центр эмбриональных тканей "ЭМСЕЛЛ" filed Critical Центр эмбриональных тканей "ЭМСЕЛЛ"
Publication of RU95120155A publication Critical patent/RU95120155A/en
Application granted granted Critical
Publication of RU2126260C1 publication Critical patent/RU2126260C1/en

Links

Claims (6)

1. Лекарственный препарат иммунокоррегирующего действия на основе клеточной суспензии, приготовленной из нативных или криоконсервированных гемопоэтических клеток эмбриональной печени и/или селезенки, отличающийся тем, что количество ядросодержащих клеток в такой суспензии составляет от 5 до 90•106 мл-1 количество колониеобразующих единиц грануломоноцитарного ряда от 20 до 80•103 мл-1, количество колониеобразующих единиц бластов - от 0,5 до 9•103 мл-1, количество ранних предшественников гемопоэза - от 1 до 9•106 мл-1.1. An immunocorrective drug based on a cell suspension prepared from native or cryopreserved hematopoietic cells of the embryonic liver and / or spleen, characterized in that the number of nucleated cells in such a suspension is from 5 to 90 • 10 6 ml -1 the number of colony forming units of granulomonocytic ranks from 20 to 80 • 10 3 ml -1 , the number of colony forming blast units is from 0.5 to 9 • 10 3 ml -1 , the number of early hematopoietic precursors is from 1 to 9 • 10 6 ml -1 . 2. Лекарственный препарат по п.1, отличающийся тем, что при криоконсервировании клеточная суспензия дополнительно содержит диметилсульфоксид в количестве 3 - 10%. 2. The drug according to claim 1, characterized in that during cryopreservation, the cell suspension additionally contains dimethyl sulfoxide in an amount of 3-10%. 3. Способ лечения сахарного диабета, заключающийся в введении биологического материала иммунокоррегирующего действия, отличающийся тем, что в качестве материала иммунокоррегирующего действия использован лекарственный препарат по п. 1. 3. A method for the treatment of diabetes mellitus, which consists in the introduction of biological material with immunocorrective action, characterized in that the drug according to claim 1 is used as the material of immunocorrective action. 4. Способ по п.3, отличающийся тем, что указанный препарат вводят в дозе 0,5 - 5 мл. 4. The method according to claim 3, characterized in that the drug is administered in a dose of 0.5 to 5 ml. 5. Способ по п.4, отличающийся тем, что указанный препарат вводят до или после терапии цитостатическими препаратами. 5. The method according to claim 4, characterized in that the drug is administered before or after therapy with cytostatic drugs. 6. Способ по любому из пп. 3 - 5, отличающийся тем, что лекарственный препарат выбирают из сформированного тканевого банка различных образцов с учетом индивидуальных показателей больного, причем при повторном введении используют препарат того же образца. 6. The method according to any one of paragraphs. 3 to 5, characterized in that the drug is selected from the formed tissue bank of various samples, taking into account the individual indicators of the patient, and when re-introduced using the drug of the same sample.
RU95120155/14A 1993-10-18 1994-10-17 Cell suspension-based immunocorrecting drug and using this drug in a method of treating diabetes mellitus RU2126260C1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
UA94020324A UA27048C2 (en) 1993-10-18 1993-10-18 Medicinal preparation of immunoreplacement activity the basis of cellular suspension and method for treatment of diabetes mellitus by the use of this preparation
UA94020324 1993-10-18

Publications (2)

Publication Number Publication Date
RU95120155A true RU95120155A (en) 1997-10-10
RU2126260C1 RU2126260C1 (en) 1999-02-20

Family

ID=21688946

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95120155/14A RU2126260C1 (en) 1993-10-18 1994-10-17 Cell suspension-based immunocorrecting drug and using this drug in a method of treating diabetes mellitus

Country Status (5)

Country Link
CA (1) CA2152078A1 (en)
NL (1) NL194693C (en)
RU (1) RU2126260C1 (en)
UA (1) UA27048C2 (en)
WO (1) WO1995011659A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA64826C2 (en) * 1998-12-16 2004-03-15 Центр Ембріональних Тканин "Емселл" Method for treating patients using cellular suspensions of embryonic tissues
RU2160112C1 (en) * 2000-04-10 2000-12-10 Сухих Геннадий Тихонович Method for producing cellular transplant from fetus tissues
RU2007112288A (en) * 2007-04-03 2008-10-10 Александр Сергеевич Ботин (RU) COMPOSITION FOR STIMULATING GROWTH AND REGENERATION OF CELLS, AND ALSO WAY OF ITS PRODUCTION

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1592637A (en) * 1978-03-22 1981-07-08 Parmer L P Lipid extract for inhibiting platelet function in blood
US4254103A (en) * 1979-06-08 1981-03-03 Institul de Cercetari Chimicofarmaceutice Hepatoprotector Factor (HF) and method of treatment
HU182087B (en) * 1980-01-15 1983-12-28 Mta Kiserleti Orvostudomanyi K Process for preparing an active substance for the selective inhibition of the multiplication of normal cells and of cells in myeloide leukemia
SU1158201A1 (en) * 1983-06-03 1985-05-30 Ленинградское Ордена Ленина,Ордена Трудового Красного Знамени Производственное Объединение Мясной Промышленности Им.С.М.Кирова Method of obtaining stimulator from mammalia spleen
US5055296A (en) * 1988-08-04 1991-10-08 Wagle Sudhakar S Method of treating chronic fatigue syndrome
IT1244879B (en) * 1990-12-11 1994-09-12 Alberto Bartorelli EXTRACTS FROM ANIMAL TISSUES, USEFUL IN THERAPY AND DIAGNOSTICS.

Similar Documents

Publication Publication Date Title
Nygren et al. Myeloid and lymphoid contribution to non-haematopoietic lineages through irradiation-induced heterotypic cell fusion
Horton et al. Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes
Becker et al. Regeneration of the ventricular myocardium in amphibians
Ogawa et al. Chemotherapy of mouse myeloma: Quantitative cell cultures predictive of response in vivo
PT742022E (en) HYDROGEL BIOLOGICALLY COMPATIBLE
BR0313197A (en) Cytotoxic agents containing potent taxanes and their therapeutic use
BR0010648A (en) Use of biodegradable microspheres that release a radiosensitizing anti-cancer agent, process of preparing biodegradable microspheres, and suspension consisting of a sterile solution
Fernbach et al. Inhibition of the mixed lymphocyte culture by peritoneal exudate cells
DE3881720D1 (en) DEVICE FOR STORAGE AND TREATMENT OF OPERATIVALLY OBTAINED.
KR950700079A (en) Use of interleukin-10 to suppress graft-vs. -Host disease
Boroughs et al. The metabolism of radionuclides by marine organisms. I. The uptake, accumulation, and loss of Strontium 89 by fishes
RU95120155A (en) DRUG IMMUNO-CORRECTIVE ACTION ON THE BASIS OF CELL SUSPENSION AND METHOD FOR TREATING DIABETES WITH USE OF THIS DRUG
RU95120165A (en) DRUG IMMUNE SUBSTITUTING ACTION ON THE BASIS OF CELLULAR SUSPENSION AND METHOD FOR TREATMENT OF THE ACQUIRED IMMUNODEFICIENCY SYNDROME (HIV INFECTION) USING THIS ANTID
Gregorevic et al. Hyperbaric oxygen improves contractile function of regenerating rat skeletal muscle after myotoxic injury
Hagemann Effect of dimethyl sulfoxide on RNA synthesis in S-180 tumor cells
JP2008031179A (en) METHOD OF USING beta-INTERFERON TO TREAT RESTENOSIS
KR890000108A (en) Pharmaceutical composition for the treatment of tumor
Szabo et al. Endothelin-A receptor antagonist BQ123 protects against myocardial and endothelial reperfusion injury
Keizman et al. Demonstration of amyloid-degrading activity in normal human serum
Bergsagel et al. Mouse myeloma: a model for studies of cell kinetics
Houlihan et al. Nerve growth-promoting properties of 1, 1, 3-tricyano-2-amino-1-propene
Vogelfanger et al. NATURALLY OCCURRING IMMUNOSUPPRESSIVE AGENTS: I. THE PRESENCE IN NORMAL PIG LIVER OF A FACTOR POSSESSING IMMUNOSUPPRESSIVE PROPERTIES WITH RESPECT TO PIG LYMPHOID CELLS IN VITRO
WO1995011659A3 (en) Pharmaceutical preparation with immuno-correcting properties based on a cell suspension, and a method of treating sugar diabetes using said preparation
Quesenberry et al. Phenotype of the engrafting stem cell in mice
Pavone-Macaluso et al. Experimental techniques for testing the sensitivity of bladder tumours to antineoplastic drugs